CH701938B1 - Whey constituents containing compositions for the preparation of chewable tablets. - Google Patents
Whey constituents containing compositions for the preparation of chewable tablets. Download PDFInfo
- Publication number
- CH701938B1 CH701938B1 CH00293/08A CH2932008A CH701938B1 CH 701938 B1 CH701938 B1 CH 701938B1 CH 00293/08 A CH00293/08 A CH 00293/08A CH 2932008 A CH2932008 A CH 2932008A CH 701938 B1 CH701938 B1 CH 701938B1
- Authority
- CH
- Switzerland
- Prior art keywords
- sep
- chewable tablets
- whey
- compositions
- compositions according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000005862 Whey Substances 0.000 title claims abstract description 25
- 102000007544 Whey Proteins Human genes 0.000 title claims abstract description 25
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 25
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 22
- 239000000470 constituent Substances 0.000 title description 3
- 239000008371 vanilla flavor Substances 0.000 claims abstract description 5
- 235000018102 proteins Nutrition 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 102000010445 Lactoferrin Human genes 0.000 claims description 7
- 108010063045 Lactoferrin Proteins 0.000 claims description 7
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 7
- 235000021242 lactoferrin Nutrition 0.000 claims description 7
- 229940078795 lactoferrin Drugs 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000003826 tablet Substances 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000000454 talc Substances 0.000 description 9
- 229910052623 talc Inorganic materials 0.000 description 9
- 235000012222 talc Nutrition 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 7
- 239000000905 isomalt Substances 0.000 description 7
- 235000010439 isomalt Nutrition 0.000 description 7
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 6
- 244000290333 Vanilla fragrans Species 0.000 description 4
- 235000009499 Vanilla fragrans Nutrition 0.000 description 4
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 4
- 229910021485 fumed silica Inorganic materials 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000220223 Fragaria Species 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- 229960001462 sodium cyclamate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
[0001] Die vorliegende Erfindung betrifft Molkebestandteile enthaltende Zusammensetzungen zur Herstellung von Kautabletten, aus solchen Zusammensetzungen herstellbare Kautabletten sowie die Verwendung solcher Zusammensetzungen bei der Behandlung von leichten bis schweren Hauterkrankungen, wie z.B. Akne. The present invention relates to compositions containing whey ingredients for the preparation of chewable tablets, to chewable tablets which can be prepared from such compositions, and to the use of such compositions in the treatment of mild to severe skin disorders, e.g. Acne.
[0002] Die erfindungsgemässen Zusammensetzungen und Kautabletten sind dadurch gekennzeichnet, dass sie, ausser Molkebestandteilen und gegebenenfalls weiteren geeigneten Ingredienzien, spezifische Aromen enthalten, und zwar Erdbeer- und Vanille-Aromen. The novel compositions and chewable tablets are characterized in that they contain, except whey components and optionally other suitable ingredients, specific flavors, namely strawberry and vanilla flavors.
[0003] Bei den erfindungsgemäss eingesetzten Molkebestandteilen kann es sich zweckmässigerweise um solche der Rindermolke handeln, insbesondere um mehr oder weniger gereinigte Bestandteile der Molke, insbesondere der Rindermolke. Molke enthält diverse hochwertige Bestandteile wie beispielsweise dem Lactoferrine, Lactoperoxydase, Alpha-Lactalbumin, Beta-Lactalbumin und Immunoglobulin. Im vorliegenden Fall ist die erfindungsgemäss verwendete Molke vorzugsweise mit Lactoferrin angereichert. Besonders bevorzugt ist eine aus Rindermolke gewonnene, 50–93 Gew.-%, insbesondere 60–95 Gew.-%, speziell 75–90 Gew.-% Lactoferrin enthaltende Proteinfraktion, welche zusätzlich basische Proteine oder Peptide mit einem Molekulargewicht von 10–60 kD enthalten kann, wie in WO 2006/098 625 A1 beschrieben. Bevorzugt ist eine Molke, welche mindestens 90 Gew.-% (>90 Gew.-%) Protein enthält, wovon mindestens 75 Gew.-% Lactoferrin ist. The whey components used according to the invention may conveniently be those of the bovine whey, in particular more or less purified constituents of the whey, in particular the bovine whey. Whey contains various high quality ingredients such as lactoferrin, lactoperoxidase, alpha-lactalbumin, beta-lactalbumin and immunoglobulin. In the present case, the whey used according to the invention is preferably enriched with lactoferrin. Particularly preferred is a 50-93 wt .-%, in particular 60-95 wt .-%, especially 75-90 wt .-% lactoferrin containing protein fraction derived from bovine whey, which additionally basic proteins or peptides with a molecular weight of 10-60 kD as described in WO 2006/098 625 A1. Preferred is a whey containing at least 90% by weight (> 90% by weight) of protein, of which at least 75% by weight is lactoferrin.
[0004] Als weitere für die erfindungsgemässen Zusammensetzungen und Kautabletten geeignete Ingredienzien kommen zweckmässigerweise in Frage: Tablettierungshilfsmittel, insbesondere Träger- und Füllstoffe, wie Isomalt (Isomaltum, gemäss European Pharmacopoeia, Seite 1837), Sorbitol, Mannitol, Erythritol, Maltitol, Xylitol, Lactose; Fliessregulierungsmittel, wie hochdisperses Siliziumdioxid; Trenn- bzw. Schmiermittel, wie Talkum, Magnesiumstearat, Stearinsäure, Natriumstearylfumarat, Calciumstearat; und/oder Geschmackskorrigentien, insbesondere Süssstoffe, wie Aspartam, Saccharin-Natrium, Natriumcyclamat, Neohesperidin, Acesulfamat. Further suitable ingredients for the compositions and chewable tablets according to the invention are suitably: tableting aids, in particular carriers and fillers, such as isomalt (Isomaltum, according to European Pharmacopoeia, page 1837), sorbitol, mannitol, erythritol, maltitol, xylitol, lactose ; Flow control agents, such as fumed silica; Lubricants, such as talc, magnesium stearate, stearic acid, sodium stearyl fumarate, calcium stearate; and / or flavoring agents, especially sweeteners such as aspartame, saccharin sodium, sodium cyclamate, neohesperidin, acesulfamate.
[0005] Erdbeer- und Vanille-Aromen für die erfindungsgemässen Zusammensetzungen und Kautabletten sind kommerziell erhältlich, beispielsweise als Erdbeer-Aroma Typ 209386 der Firma Symrise GmbH & Co. KG, D-37603 Holzminden oder als Vanille-Aroma Typ 84262-31 der Firma Givaudan AG, CH-8600 Dübendorf. Strawberry and vanilla flavors for the novel compositions and chewable tablets are commercially available, for example as strawberry flavor type 209386 from Symrise GmbH & Co. KG, D-37603 Holzminden or as vanilla flavor type 84262-31 of the company Givaudan AG, CH-8600 Dübendorf.
[0006] Ausser den Molkebestandteilen können die erfindungsgemässen Zusammensetzungen und Kautabletten noch weitere physiologisch wirksame Ingredienzien enthalten, wie zum Beispiel: von Säugern abgeleitete bioaktive Proteine, wie Lactoperoxidase; Glycoproteine; Enzyme; Kohlenhydrate; Polysaccharide, wie Pektin, Carboxymethylcellulose, Carragenane; Heparine; Fettsäuren; Peptide; Aminosäuren; Wachstumsfaktoren; Lysozyme; Histatine; Cystatine; Casein, Casein-Phosphopeptide (CPP); Peptide oder Peptidmischungen, welche bezüglich einer oder mehrerer spezifischer, z.B. (konditionell) essentieller, Aminosäuren angereichert sind, wie Glutamin, Cystein, Glycin, Arginin, Tryptophan etc.; Antihypertensive Peptide; Retinoide; Vitamine; und/oder Hormone. In addition to the whey ingredients, the compositions of the invention and chewable tablets may contain other physiologically active ingredients, such as: mammalian derived bioactive proteins such as lactoperoxidase; glycoproteins; enzymes; Carbohydrates; Polysaccharides such as pectin, carboxymethyl cellulose, carragenans; heparins; fatty acids; peptides; Amino acids; Growth factors; Lysozyme; histatins; cystatins; Casein, casein phosphopeptides (CPP); Peptides or peptide mixtures which are associated with one or more specific, e.g. (conditionally) more essential, amino acids are enriched, such as glutamine, cysteine, glycine, arginine, tryptophan, etc .; Antihypertensive peptides; retinoids; vitamins; and / or hormones.
[0007] Die erfindungsgemässen Zusammensetzungen können auf konventionelle Weise hergestellt und zu den erfindungsgemässen Kautabletten verarbeitet werden. In den erfindungsgemässen Kautabletten machen die Molkebestandteile zweckmässigerweise 5 Gew.-% bis 30 Gew.-%, vorzugsweise 10 Gew.-% bis 20 Gew.-% des Gesamtgewichts der Kautablette aus. The novel compositions can be prepared in a conventional manner and processed into the chewable tablets according to the invention. In the chewable tablets according to the invention, the whey constituents expediently comprise from 5% by weight to 30% by weight, preferably from 10% by weight to 20% by weight, of the total weight of the chewable tablet.
[0008] Die erfindungsgemässen Zusammensetzungen bzw. die aus ihnen herstellbaren Kautabletten können bei der Behandlung von leichten bis schweren Hauterkrankungen verwendet werden, insbesondere bei der Behandlung von Akne. Die Dosierung richtet sich nach verschiedenen individuellen Faktoren des Patienten, wie Alter, genereller Zustand und Ernährungszustand sowie Schwere der Erkrankung, und sie muss vom behandelnden Arzt diesen Faktoren angepasst werden. Normalerweise dürfte aber eine Dosis angebracht sein, weiche pro Tag einer Einnahme von 10 mg bis 1200 mg, vorzugsweise 50 mg bis 200 mg, besonders bevorzugt 100 mg bis 200 mg, Molkebestandteilen entspricht. The compositions according to the invention or the chewable tablets which can be prepared from them can be used in the treatment of mild to severe skin diseases, in particular in the treatment of acne. The dosage depends on various individual factors of the patient, such as age, general condition and nutritional status and severity of the disease, and it must be adapted by the attending physician to these factors. Normally, however, a dose should be appropriate which corresponds to a daily intake of 10 mg to 1200 mg, preferably 50 mg to 200 mg, particularly preferably 100 mg to 200 mg of whey components.
[0009] Die nachfolgenden Beispiele betreffen die Formulierung von erfindungsgemässen Kautabletten, enthaltend als Molkebestandteil eine 85 Gew.-% Lactoferrin enthaltende Proteinfraktion; sie sollen die Erfindung näher erläutern, ihren Umfang jedoch in keiner Weise beschränken. The following examples relate to the formulation of chewable tablets according to the invention, containing as the whey ingredient a protein fraction containing 85% by weight lactoferrin; they are intended to illustrate the invention in more detail, but limit its scope in any way.
Beispiel 1example 1
[0010] <tb>Bestandteile<sep>Menge pro Tablette [mg]<sep>Menge pro Ansatz [kg] <tb>Proteinfraktion<sep>100.00<sep>100.00 <tb>Isomalt<sep>638.00<sep>633.00 <tb>Aroma Erdbeere<sep>5.00<sep>5.00 <tb>Aroma Vanille<sep>10.00<sep>10.00 <tb>Talkum<sep>35.00<sep>35.00 <tb>Magnesiumstearat<sep>12.00<sep>12. 00 <tb>Total<sep>800. 00<sep>800.00[0010] <tb> Ingredients <sep> Quantity per tablet [mg] <sep> Quantity per batch [kg] <Tb> protein fraction <sep> 100.00 <sep> 100.00 <Tb> isomalt <sep> 638.00 <sep> 633.00 <tb> Aroma Strawberry <sep> 5.00 <sep> 5.00 <tb> Aroma Vanilla <sep> 10.00 <sep> 10.00 <Tb> Talc <sep> 35.00 <sep> 35.00 <Tb> Magnesium stearate <sep> 12:00 <sep> 12th 00 <Tb> Total <sep> 800th 00 <sep> 800.00
[0011] Die Proteinfraktion und die beiden Aromen werden zusammen mit dem Isomalt gesiebt (1.25 mm} und dann 15 Minuten in einem Freifallmischer gemischt. Dann wird das Talkum zugegeben, erneut für fünf Minuten gemischt, worauf das Magnesiumstearat zugegeben und erneut für fünf Minuten gemischt wird. Die Mischung wird auf einer Rundläufertablettenpresse zu dreieckigen Tabletten mit einer Seitenlänge von 14.5 mm und einer Härte von 60 N bis 180 M verpresst. The protein fraction and the two flavors are sieved together with the isomalt (1.25 mm) and then mixed for 15 minutes in a tumbler mixer, then the talc is added, mixed again for five minutes, then the magnesium stearate is added and mixed again for five minutes The mixture is pressed on a rotary tablet press into triangular tablets 14.5 mm long and 60 N to 180 M in hardness.
Beispiel 2Example 2
[0012] <tb>Bestandteile<sep>Menge pro Tablette [mg]<sep>Menge pro Ansatz [kg] <tb>Proteinfraktion<sep>100.00<sep>100.00 <tb>Isomalt<sep>538.50<sep>538.50 <tb>Aspartam<sep>2.00<sep>2.00 <tb>Aroma Erdbeere<sep>4.50<sep>4.50 <tb>Aroma Vanille<sep>9.00<sep>9.00 <tb>Siliciumdioxid, hochdispers<sep>1. 00<sep>1.00 <tb>Talkum<sep>35. 00<sep>35.00 <tb>Magnesiumstearat<sep>10.00<sep>10.00 <tb>Total<sep>700.00<sep>700.00[0012] <tb> Ingredients <sep> Quantity per tablet [mg] <sep> Quantity per batch [kg] <Tb> protein fraction <sep> 100.00 <sep> 100.00 <Tb> isomalt <sep> 538.50 <sep> 538.50 <Tb> Aspartame <sep> 2:00 <sep> 2:00 <tb> Aroma Strawberry <sep> 4.50 <sep> 4.50 <tb> Aroma Vanilla <sep> 9.00 <sep> 9.00 <tb> Silica, fumed <sep> 1. 00 <sep> 1:00 <Tb> Talc <sep> 35th 00 <sep> 35.00 <Tb> Magnesium stearate <sep> 10:00 <sep> 10:00 <Tb> Total <sep> 700.00 <sep> 700.00
[0013] Aspartam und die beiden Aromen werden für fünf Minuten in einem Freifallmischer vorgemischt. Diese Vormischung wird zusammen mit der Proteinfraktion und dem Isomalt gesiebt (1.25 mm) und für 15 Minuten in einem Freifallmischer vermischt. Danach wird das hochdisperse Siliziumdioxid zugegeben, erneut für fünf Minuten gemischt, anschliessend das Talkum zugegeben und erneut für fünf Minuten gemischt, worauf das Magnesiumstearat zugegeben und erneut für fünf Minuten vermischt wird. Die Mischung wird auf einer Rundläufertablettenpresse zu dreieckigen Tabletten mit einer Seitenlänge von 13.2 mm und einer Härte von 60 N bis 120 M verpresst. Aspartame and the two flavors are premixed for five minutes in a free fall mixer. This premix is sieved together with the protein fraction and isomalt (1.25 mm) and mixed for 15 minutes in a tumbler mixer. Thereafter, the fumed silica is added, mixed again for five minutes, then the talc is added and mixed again for five minutes, after which the magnesium stearate is added and mixed again for five minutes. The mixture is pressed on a rotary tablet press into triangular tablets with a side length of 13.2 mm and a hardness of 60 N to 120 M.
Beispiel 3Example 3
[0014] <tb>Bestandteile<sep>Menge pro Tablette [mg]<sep>Menge pro Ansatz [kg] <tb>Proteinfraktion<sep>100.00<sep>100.00 <tb>Isomalt<sep>445.98<sep>445.98 <tb>Natrium-Cyclamat<sep>0.60<sep>0.60 <tb>Saccharin-Natrium<sep>0.42<sep>0.42 <tb>Aroma Erdbeere<sep>4.00<sep>4.00 <tb>Aroma Vanille<sep>8.00<sep>8.00 <tb>Siliciumdioxid, hochdispers<sep>1.00<sep>1.00 <tb>Talkum<sep>30.00<sep>30.00 <tb>Magnesiumstearat<sep>10.00<sep>10.00 <tb>Total<sep>600.00<sep>600.00[0014] <tb> Ingredients <sep> Quantity per tablet [mg] <sep> Quantity per batch [kg] <Tb> protein fraction <sep> 100.00 <sep> 100.00 <Tb> isomalt <sep> 445.98 <sep> 445.98 <Tb> sodium cyclamate <sep> 0.60 <sep> 0.60 <Tb> Sodium Saccharin <sep> 12:42 <sep> 00:42 <tb> Aroma Strawberry <sep> 4.00 <sep> 4.00 <tb> Aroma Vanilla <sep> 8.00 <sep> 8.00 <tb> Silica, fumed <sep> 1.00 <sep> 1.00 <Tb> Talc <sep> 30.00 <sep> 30.00 <Tb> Magnesium stearate <sep> 10:00 <sep> 10:00 <Tb> Total <sep> 600.00 <sep> 600.00
[0015] Das Natrium-Cyclamat und das Saccharin-Natrium werden zusammen mit den beiden Aromen für 5 Minuten in einem Freifallmischer vorgemischt. Diese Vermischung wird zusammen mit der Proteinfraktion und dem Isomalt gesiebt (1.25 mm) und für 15 Minuten in einem Freifallmischer vermischt. Danach wird das hochdisperse Siliciumdioxid zugegeben, erneut für fünf Minuten gemischt, anschliessend das Talkum zugegeben und erneut für fünf Minuten gemischt, worauf das Magnesiumstearat zugegeben und erneut für fünf Minuten vermischt wird. Die Mischung wird auf einer Rundläufertablettenpresse zu dreieckigen Tabletten mit einer Seitenlänge von 13.2 mm und einer Härte von 60 bis 120 N verpresst. The sodium cyclamate and the saccharin sodium are premixed together with the two flavors for 5 minutes in a tumbler mixer. This mixture is sieved together with the protein fraction and isomalt (1.25 mm) and mixed for 15 minutes in a tumbler mixer. Thereafter, the fumed silica is added, mixed again for five minutes, then the talc is added and mixed again for five minutes, after which the magnesium stearate is added and mixed again for five minutes. The mixture is pressed on a rotary tablet press into triangular tablets with a side length of 13.2 mm and a hardness of 60 to 120 N.
Beispiel 4Example 4
[0016] <tb>Bestandteil<sep>Menge pro Tablette [mg]<sep>Menge pro Ansatz [kg] <tb>Proteinfraktion<sep>100.00<sep>100.00 <tb>Sorbitol<sep>383.00<sep>383.00 <tb>Saccharin-Natrium<sep>2.00<sep>2.00 <tb>Aroma Erdbeere<sep>4.00<sep>4.00 <tb>Aroma Vanille<sep>8.00<sep>8.00 <tb>Siliciumdioxid, hochdispres<sep>3.00<sep>3.00 <tb>Talkum<sep>30.00<sep>30.00 <tb>Magnesiumstearat<sep>10.00<sep>10.00 <tb>Total<sep>540.00<sep>540.00[0016] <tb> Component <sep> Quantity per tablet [mg] <sep> Quantity per batch [kg] <Tb> protein fraction <sep> 100.00 <sep> 100.00 <Tb> sorbitol <sep> 383.00 <sep> 383.00 <Tb> Sodium Saccharin <sep> 2:00 <sep> 2:00 <tb> Aroma Strawberry <sep> 4.00 <sep> 4.00 <tb> Aroma Vanilla <sep> 8.00 <sep> 8.00 <tb> Silica, high-density <sep> 3.00 <sep> 3.00 <Tb> Talc <sep> 30.00 <sep> 30.00 <Tb> Magnesium stearate <sep> 10:00 <sep> 10:00 <Tb> Total <sep> 540.00 <sep> 540.00
[0017] Das Saccharin-Natrium und die beiden Aromen werden für fünf Minuten in einem Freifallmischer vorgemischt. Diese Vormischung wird zusammen mit der Proteinfraktion und dem Sorbitol gesiebt (1.25 mm) und für 15 Minuten in einem Freifallmischer gemischt. Danach wird das hochdisperse Siliziumdioxid zugegeben, erneut für fünf Minuten gemischt, anschliessend das Talkum zugegeben und erneut für fünf Minuten gemischt, worauf das Magnesiumstearat zugegeben und erneut für fünf Minuten vermischt wird. Die Mischung wird auf einer Rundläufertablettenpresse zu dreieckigen Tabletten mit einer Seitenlänge von 12.5 min und einer Härte von 60 bis 120 N verpresst. The saccharin sodium and the two flavors are premixed for five minutes in a tumbler mixer. This premix is sieved together with the protein fraction and sorbitol (1.25 mm) and mixed for 15 minutes in a tumbler mixer. Thereafter, the fumed silica is added, mixed again for five minutes, then the talc is added and mixed again for five minutes, after which the magnesium stearate is added and mixed again for five minutes. The mixture is pressed on a rotary tablet press into triangular tablets with a side length of 12.5 minutes and a hardness of 60 to 120 N.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH00293/08A CH701938B1 (en) | 2008-02-28 | 2008-02-28 | Whey constituents containing compositions for the preparation of chewable tablets. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH00293/08A CH701938B1 (en) | 2008-02-28 | 2008-02-28 | Whey constituents containing compositions for the preparation of chewable tablets. |
Publications (1)
Publication Number | Publication Date |
---|---|
CH701938B1 true CH701938B1 (en) | 2011-04-15 |
Family
ID=43857959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH00293/08A CH701938B1 (en) | 2008-02-28 | 2008-02-28 | Whey constituents containing compositions for the preparation of chewable tablets. |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH701938B1 (en) |
-
2008
- 2008-02-28 CH CH00293/08A patent/CH701938B1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3108079C2 (en) | Nutriensolution containing aqueous oligopeptides | |
DE60308810T2 (en) | EXCITEMENT OF IN-VIVO SYNTHESIS OF PROTEINS CONTAINING COMPOSITIONS CONTAINING LEUCIN | |
EP0254289B1 (en) | Agent for the treatment of arthrosis | |
DE602006000511T2 (en) | DERMATOLOGICAL USE OF PROTEINS FROM MILK | |
JP5276813B2 (en) | Elastin-degrading peptide, method for producing elastin and its enzyme-degrading peptide | |
EP1909601B1 (en) | Liquid formulation based on a guanidinoacetic acid component | |
JP5798648B2 (en) | Anti-fatigue agent containing amino acid composition | |
DE102006018293A1 (en) | Pediatric amino acid solution for parenteral nutrition | |
JPH07278012A (en) | Metabolic promoter and food containing the same blended | |
JP2006265177A (en) | Composition for improving tic disorder | |
JP5064714B2 (en) | Anti-stress composition | |
WO2007009529A2 (en) | Calcium-peptide component | |
EP1916913A2 (en) | Protein composition for treating a physiologically caused, clinically normal increased need for protein | |
WO2017119481A1 (en) | Cyclic dipeptide-containing composition for preventing neurological diseases | |
EP1410721B2 (en) | Process for manufacturing an isomaltulose-containing enteral food | |
EP0234186B1 (en) | Use of oligopeptids for the treatment of cerebral disorders | |
JPH06345664A (en) | New composition for suppressing elevation of blood pressure | |
CH701938B1 (en) | Whey constituents containing compositions for the preparation of chewable tablets. | |
WO2017002840A1 (en) | Endothelin receptor antagonist composition | |
DE60216523T2 (en) | PREPARATION AND USE OF SOY PROTEIN HYDROLYSATES ENRICHED WITH BRANCHED AMINO ACIDS | |
DE2712777A1 (en) | MEDICINAL PRODUCTS TO PROMOTE PROTEIN SYNTHESIS AND TO PRESERVE NITROGEN IN THE BODY | |
DE3943424A1 (en) | Solns. for intravenous nutrition - contg. alpha-keto acids, for patients with kidney conditions, avoids nitrogen cpd. build-up | |
JP6840647B2 (en) | Liquid composition, its cloudiness improving agent, odor improving agent, and manufacturing method | |
DE202006019504U1 (en) | Protein preparation, useful e.g. for weight-controlling diet comprises soya- and milk-protein, carnitine, conjugated linoleic acid, vitamins and trace elements and/or mineral materials | |
WO2020038768A1 (en) | Beverage and solid mixture for the production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PFA | Name/firm changed |
Owner name: MEPHA GMBH Free format text: MEPHA AG#DORNACHERSTRASSE 114#4147 AESCH BL (CH) -TRANSFER TO- MEPHA GMBH#DORNACHERSTRASSE 114#4147 AESCH (CH) |
|
PUE | Assignment |
Owner name: MEPHA SCHWEIZ AG Free format text: MEPHA GMBH#DORNACHERSTRASSE 114#4147 AESCH (CH) -TRANSFER TO- MEPHA SCHWEIZ AG#DORNACHERSTRASSE 114 POSTFACH 445#4147 AESCH (CH) |
|
PL | Patent ceased |